Our Syndicate concept opens up radical new ways of translating good science into great diagnostics, biomarkers and medicines. They will be long-term consortia anchored on their diseases and cornerstoned by medical charities. They will also contain biopharma, SMEs, technologists and larger companies with a focus on that disease.
- Charities bring clinical realities and real unmet patient need
- Industrial players know where collaborative R&D will overcome technology and process barriers
- Focussed funders bring the long-term resources that support portfolios of potential products
- We will manage the consortium process and provide the framework for the R&D to occur, through the CRO community and within the Syndicate
New models like this put the patient at the beginning of discovery. They also provide extra robustness and bring variety to the environment.
Tackling real patient need in three initial priority areas
Syndicates develop an overview of the key problems, priorities and gaps in existing medicines, infrastructure, or capacity currently hindering progress in three priority areas:
- Infectious diseases particularly those caused by multi-drug resistant bacteria that remain a global threat to human health
- Inflammatory diseases that form a group of non-cancerous conditions such as asthma, rheumatoid arthritis and macular degeneration
- Diseases of the central nervous system such as Alzheimer’s and Parkinson’s, which have a high genetic component in some cases and typically face a challenging route to the clinic as well as difficulties in drug delivery
Get in touch now if you are a research charity, a translational researcher or an investor wanting a new approach to making high value medicines, diagnostics or biomarkers.